Biomea Fusion announces anticipated 2024 corporate milestones

Biomea Fusion announced that Thomas Butler, Biomea Fusion’s CEO and Chairman of the Board, will present recent clinical progress and 2024 corporate milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST. DIABETES: COVALENT-111: Anticipated 2024 Milestones: On track to complete escalation portion of COVALENT-111 and present 26-week data, five months after last dose of BMF-219, from cohorts that were dosed with BMF-219 for 28 days, at the Advanced Technologies and Treatments for Diabetes Meeting in March 2024. On track to finish enrolling three expansion cohorts of COVALENT-111 and provide initial data in 2024. COVALENT-112: Anticipated 2024 Milestones: Complete enrollment of the open label portion. On track to establish the initial proof of concept based on clinical data in type 1 diabetes patients treated in COVALENT-112 with BMF-219. ONCOLOGY: COVALENT-101: Anticipated 2024 Milestones: On track to complete dose escalation portion of COVALENT-101 in liquid tumors and establish recommended Phase II dose. COVALENT-102: Anticipated 2024 Milestones: On track to complete dose escalation portion of COVALENT-102 in solid tumors and establish recommended Phase II dose. COVALENT-103: Anticipated 2024 Milestones: On track to complete dose escalation portion of COVALENT-103 and establish recommended Phase II dose. FUSION SYSTEM DISCOVERY PLATFORM: Anticipated 2024 Milestones: On track to announce a third development candidate from the Biomea FUSION Platform technology.